A Phase 1/2 Study of ABBV-383 in Combination with Anti-Myeloma Agents for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Primary Objectives
To characterize the safety, toxicity, and tolerability of etentamig when co-administered with
iberdomide in subjects with RRMM.
To determine the recommended doses of etentamig and iberdomide combination treatment in
subjects with RRMM.
Secondary Objectives
To evaluate the preliminary anti-MM activity of etentamig when co-administered with
Iberdomide.
To characterize the PK and the immunogenicity of etentamig, as well as the PK of iberdomide
and its metabolite M12, when administered in combination as a regimen.
Etentamig
Iberdomide
- Rutgers University
Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance of 0 to 1. - Must have confirmed diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM) after the participant's last treatment, as outlined in the protocol. - All participants must have measurable diseases per central laboratory as outlined in protocol Exclusion Criteria: - Has received prior etentamig treatment. - Prior exposure to BCMA-targeted therapy as noted in the protocol. - Has received prior cereblon E3 ligase modulatory drug (CELMoD) (iberdomide or mezigdomide).
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.